---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-162233"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-07-22T23:59:59+00:00"
generated_at: "2026-05-18T04:16:13.445377+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D

## Summary
- Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.
- Appointed Dr. Ludger Dinkelborg, former Life Molecular CEO, as Head of R&D effective Aug 1, 2025.
- Transaction adds commercial infrastructure, R&D capabilities, and international footprint for Alzheimer's radiodiagnostics.
- Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers.

## SEC filing metadata
- accession: 0001193125-25-162233
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-07-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/0001193125-25-162233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/d89717d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-162233
- JSON: https://secwatch.observer/filing/0001193125-25-162233.json
- Plain text: https://secwatch.observer/filing/0001193125-25-162233.txt

## Key facts
- M&A Transactions
  Lantheus Holdings, Inc. completed an acquisition involving Life Medical Group Limited for $350 million (closed 2025-07-21).
  - Action: acquisition
  - Counterparty: Life Medical Group Limited
  - Consideration: $350 million
  - Closing: 2025-07-21
  source text: the Transaction pursuant to the Agreement. In accordance with the Agreement, upon the closing of the Transaction, the Purchaser paid the Seller an upfront cash payment of $350 million (following applicable purchase price adjustments under the Agreement) in exchange for all of the outstanding share capital of Life Molecular. The foregoing description of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/0001193125-25-162233-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.